指南与共识神经免疫神经肌肉病

实践咨询:胸腺切除术治疗重症肌无力(实践参数更新)

Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
指南 / 共识 · Neurology · 2020-03-25

美国神经病学学会指南制定小组系统评价胸腺切除术治疗重症肌无力的证据。一项I类研究显示,65岁以下非胸腺瘤AChR抗体阳性全身型MG患者,泼尼松联合胸腺切除术比单用泼尼松更易达到微小表现状态(36个月风险差20%,95%CI 1.6%-37%)。推荐与患者讨论胸腺切除术(B级),并告知微创术式获益不确定(B级)。

要点

  • 非胸腺瘤AChR抗体阳性全身型MG患者,胸腺切除术联合泼尼松可能更易达到微小表现状态。
  • 36个月时达到微小表现状态的风险差为20%(95%CI 1.6%-37%),证据置信度为中等。
  • 微创胸腺切除术是否能获得与扩大的经胸骨胸腺切除术相同的获益尚不确定。

核心结论

  • 对于非胸腺瘤AChR抗体阳性全身型MG患者,胸腺切除术联合泼尼松比单用泼尼松更可能提高达到微小表现状态的机会。

研究设计与样本

  • 美国神经病学学会指南制定小组系统评价证据并制定实践推荐。
  • 纳入一项I类研究,对象为65岁以下非胸腺瘤AChR抗体阳性全身型MG患者。

主要发现

  • 口服泼尼松联合胸腺切除术组比单用泼尼松组临床结局更好,达到微小表现状态的概率更高。
  • 36个月时达到微小表现状态的风险差为20%(95%CI 1.6%-37%),证据置信度为中等。

关键数值与推荐

  • 推荐临床医生与AChR抗体阳性全身型MG患者讨论胸腺切除术治疗(B级)。
  • 推荐告知考虑微创胸腺切除术的患者,扩大的经胸骨胸腺切除术的获益是否也能通过微创途径获得尚不确定(B级)。

临床怎么用

  • 对AChR抗体阳性全身型MG患者,应个体化讨论胸腺切除术的获益与风险。
  • 选择微创胸腺切除术时,需告知患者其获益证据不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To review updated evidence regarding the effectiveness of thymectomy for treating patients with myasthenia gravis (MG). METHODS: The practice advisory panel performed a systematic review and developed practice recommendations using methods developed by the American Academy of Neurology. RESULTS: One Class I study of patients younger than 65 years with nonthymomatous acetylcholine receptor antibody-positive (AChR ab+) generalized MG demonstrated better clinical outcomes in patients treated with oral prednisone and undergoing thymectomy compared with patients treated with prednisone alone, including an increased probability of attaining minimal manifestation status (no symptoms or functional limitations). CONCLUSION: For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence). RECOMMENDATIONS: Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B). Clinicians should counsel patients with AChR ab+ generalized MG considering minimally invasive thymectomy techniques that it is uncertain whether the benefit attained by extended transsternal thymectomy will also be attained by minimally invasive approaches (Level B).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gronseth GS, Barohn R, Narayanaswami P, et al. Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2020. PMID: 32213645. doi:10.1212/WNL.0000000000009294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。